Streamlined Geriatric and Oncological Evaluation Based On IC Technology

Prior treatment

• Participating to an interventional clinical trial with a non-registered anticancer drug or to another geriatric intervention trial.

Other illness

• Mental illness/cognitive impairment that limits ability to provide consent or complete trial procedures.

Other

• Patients and caregivers are unable or unwilling to use ICT-devices (tablet,computer, smartphone) or the Internet according to protocol.
• Patient already included in this study.

• \- General inclusion criteria
• Age ≥ 70 years old.
• New or progressive cancer (breast, lung, colorectal, prostate), histologically proven or strong clinical suspicion, fulfilling the tumor specific criteria.
• Estimated life expectancy greater than 6 months.
• At least one moderate/severe multimorbidity inclusion criteria other than current cancer (see separate list under 5.3).
• Patients must be willing and able to comply with study procedures.
• Voluntarily signed and dated written informed consents prior to any study specific procedure.
• QLQ-C30 Quality of Life Questionnaire fully completed at baseline, before inclusion.
• Patients affiliated with a French social security scheme in accordance with the French law on biomedical research (Article 1121-11 of the French Code of Public health).
  • Tumor specific inclusion criteria
• Specific inclusion criteria for breast cancer:
  • 9.1. Non-metastatic breast cancer (M0):
  • \- No prior treatment for the current breast cancer.
  • \- All 3 criteria required:
  • o Clinical staging: cT2-3-4 Nany, or cTany N1-2-3;
  • The cancer specialist considers\* surgery;
  • The cancer specialist considers\* radiotherapy and/or chemotherapy. 9.2. Metastatic breast cancer (M1): Both criteria required:
  • The cancer specialist considers\* chemotherapy or PARP-inhibitors or mTOR-inhibitors / PIK3CA inhibitors; Previous endocrine therapy +/- CDK4/6 inhibitors is allowed;
  • The patient received maximum 1 prior line of chemotherapy for metastatic disease.
  • 'consider' implies that this treatment may be a treatment option for this patient in this particular setting. If at a later point, a different treatment choice is made, the patient remains eligible.
• Specific inclusion criteria for colorectal cancer:
  • 10.1. Non-metastatic colorectal cancer (M0):
  • \- No prior therapy for the current tumor in the recruiting hospital
  • At least one of the 3 criteria required:
  • o The cancer specialist considers\* surgery;
  • The cancer specialist considers\* radiotherapy;
  • The cancer specialist considers\* chemotherapy and/or immunotherapy. 10.2. Metastatic colorectal cancer (M1):
  • The cancer specialist considers\* first or second line systemic therapy and/or radiotherapy (+/- surgery). No previous chemotherapy allowed except adjuvant/perioperative chemotherapy stopped for more than 12 months.
  • 'consider' implies that this treatment may be a treatment option for this patient in this particular setting. If at a later point, a different treatment choice is made, the patient remains eligible.
• Specific inclusion criteria for lung cancer:
  • 11.1. Non-metastatic lung cancer (M0):
• No prior therapy for the current tumor in the recruiting hospital
• At least one of the 3 criteria required:
  • The cancer specialist considers\* surgery (patients considered for treatment with percutaneous thermoablation alone are not eligible);
  • The cancer specialist considers\* radiotherapy (except SBRT);
  • The cancer specialist considers\* systemic therapy. Possible systemic therapies are chemotherapy and/or immune therapy and/or targeted therapy. Patients only considered\* for monotherapy with anti-EGFR TKI or somatostatin analog are not eligible.
  • 11.2. Metastatic lung cancer (M1):
• The cancer specialist considers\* first or second line systemic therapy. Possible systemic therapies are chemotherapy and/or immune therapy and/or targeted therapy. Patients only considered\* for monotherapy with anti-EGFR TKI or somatostatin analog are not eligible.
  • \*'consider' implies that this treatment may be a treatment option for this patient in this particular setting. If at a later point, a different treatment choice is made, the patient remains eligible.
  • 12\. Specific inclusion criteria for prostate cancer: 12.1. Non-metastatic prostate cancer (M0): one of the following:
• First diagnosis M0 prostate cancer (no therapy received yet for prostate cancer): at least one of the 2 criteria required:
  • o The cancer specialist considers\* radiotherapy;
  • o The cancer specialist considers\* hormone therapy (ADT +/- combination Abiraterone and Prednisone).
• Salvage treatment M0 prostate cancer (received prior surgery at least 6 months before):
  • o The cancer specialist considers\* radiotherapy (+/- ADT)
• Non-metastatic castration resistant prostate cancer:
  • The cancer specialist considers\* treatment intensification (ADT + Enzalutamide or Apalutamide or Darolutamide).
  • 12.2. Metastatic prostate cancer (M1): - The cancer specialist considers\* treatment with Abiraterone or Enzalutamide or Apalutamide, or Docetaxel or Cabazitaxel or PARP-inhibitors or Lutetium PSMA.
  • \*'consider' implies that this treatment may be a treatment option for this patient in this particular setting. If at a later point, a different treatment choice is made, the patient remains eligible.